AC Immune Advances Pipeline with Key Milestones and $12M Takeda Payment — AC Immune SA

Event summary

AC Immune reported CHF75.4 million in cash resources as of June 30, 2026, sufficient to fund operations into Q4 2027.
The company received a $12 million milestone payment from Takeda for initiating the AD4 cohort in the ABATE trial of ACI-24.
Phase 2 VacSYn trial of ACI-7104 in Parkinson’s disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation.
AC Immune's wholly-owned pipeline includes three clinical-stage programs targeting α-synuclein, TDP-43, and NLRP3.

The big picture

AC Immune is focusing on its wholly-owned programs while leveraging strategic partnerships to advance its pipeline. The company's ability to generate milestone payments from partners like Takeda and Lilly underscores the strength of its neuroscience platform, but its long-term success will depend on the clinical outcomes of its key programs.

What we're watching

Clinical Catalysts: The pace at which AC Immune delivers final data from Part 1 of the Phase 2 VacSYn trial and initial results from the ACI-19764 Phase 1 trial will determine investor confidence in its wholly-owned programs.
Financial Sustainability: Whether AC Immune can sustain its cash runway into Q4 2027 without additional funding rounds or milestone payments from partners.
Strategic Partnerships: How the amended agreement with Lilly and continued collaboration with Takeda will impact the development of new lead Tau Morphomer candidates and potential back-up compounds.